Human growth hormone presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 577-586

  Zhong, Jie ^a   Matsumoto, Koji ^a   De Kluyver, Rachel ^a   Fernando, Germain J P ^a   Leggatt, Graham R ^a   Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Human growth hormone (hGH); Keratinocyte; Tolerance; Transplantation; Tumour immunology

Indexed keywords

ANTIBODY; AUTOANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; GROWTH HORMONE ANTIBODY; GROWTH HORMONE DERIVATIVE; HUMAN GROWTH HORMONE; NEO AUTOANTIGEN; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE MARKER; EPITHELIUM CELL; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; ISOGRAFT; K14HGH TRANSGENIC SKIN GRAFT; KERATINOCYTE; MOUSE; NONHUMAN; SKIN GRAFT; SKIN INFILTRATE; SOMATIC CELL; TRANSGENIC MOUSE; TRANSGENICS; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GROWTH HORMONE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); SKIN TRANSPLANTATION; TRANSPLANTATION;

ANIMALIA; MUS MUSCULUS;

EID: 8844250252     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01292.x     Document Type: Article

References (54)

1. Frazer IH, De Kluyver R, Leggatt GR et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 2001; 167: 6180-87.
2. Frazer IH, Dunn L, Fernando GJ, Tindle RW, Lambert P, Lambert P. HPV16E7 transgenic skin is not rejected in E7 immunised mice. J. Cell. Biochem. 1995; 19A: 310.
3. Azoury-Ziadeh R, Herd K, Fernando GJ, Lambert P, Frazer IH, Tindle RW. Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. Virus Res. 2001; 73: 189-99.
4. Munger K, Basile JR, Duensing S et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20: 7888-98.
5. Ke LD, Adler-Storthz K, Mitchell MF, Clayman GL, Chen Z. Expression of human papillomavirus E7 mRNA in human oral and cervical neoplasia and cell lines. Oral Oncol. 1999; 35: 415-20.
6. Masumoto N, Fujii T, Ishikawa M et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum. Pathol. 2003; 34: 778-83.
7. Azukizawa H, Kosaka H, Sano S et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur. J. Immunol. 2003; 33: 1879-88.
8. Byrne C, Tainsky M, Fuchs E. Programming gene expression in developing epidermis. Development 1994; 120: 2369-83.
9. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E. Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc. Natl Acad. Sci. USA 1989; 86: 1563-7.
10. Stephen Harvey CGS, Daughaday WH. Growth Hormone. Boca Raton, FL: CRC Press, 1995.
11. Shepherd DM, Kerkvliet NI. Disruption of CD154: CD40 blocks generation of allograft immunity without affecting APC activation. J. Immunol. 1999; 163: 2470-77.
12. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 1983; 131: 2178-83.
13. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 1980; 125: 2665-72.
14. Zhong J, Gilbertson B, Cheers C. Apoptosis of CD4+ and CD8+ T cells during experimental infection with Mycobacterium avium is controlled by Fas/FasL and Bcl-2-sensitive pathways, respectively. Immunol. Cell Biol. 2003; 81: 480-86.
15. Frazer IH, Leippe DM, Dunn LA et al. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 1995; 55: 2635-9.
16. Wang X, Zinkel S, Polonsky K, Fuchs E. Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc. Natl Acad. Sci. USA 1997; 94: 219-26.
17. de Mello-Coelho V, Gagnerault MC, Souberbielle JC et al. Growth hormone and its receptor are expressed in human thymic cells. Endocrinology 1998; 139: 3837-42.
18. Chen N, Gao Q, Field EH. Prevention of Th1 response is critical for tolerance. Transplantation 1996; 61: 1076-83.
19. Donckier V, Flamand V, Desalle F et al. IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur. J. Immunol. 1998; 28: 1426-30.
20. Gao Q, Chen N, Rouse TM, Field EH. The role of interleukin-4 in the induction phase of allogeneic neonatal tolerance. Transplantation 1996; 62: 1847-54.
21. Qin L, Ding Y, Tahara H, Bromberg JS. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft. J. Immunol. 2001; 166: 2385-93.
22. He XY, Verma N, Chen J, Robinson C, Boyd R, Hall BM. 1L-5 prolongs allograft survival by downregulating IL-2 and IFN-gamma cytokines. Transplant. Proc. 2001; 33: 703-4.
23. Estes DM, Brown WC. Type 1 and type 2 responses in regulation of Ig isotype expression in cattle. Vet. Immunol. Immunopathol. 2002; 90: 1-10.
24. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 1996; 153: 85-106.
25. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993; 177: 925-35.
26. Koch F, Stanzl U, Jennewein P et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 1996; 184: 741-6.
27. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996; 184: 747-52.
28. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. 1996; 156: 3932-8.
29. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
30. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu. Rev. Immunol. 1992; 10: 333-58.
31. Trumble T, Gunlikson R, Parvin D. A comparison of immune response to nerve and skin allografts. J. Reconstr. Microsurg. 1993; 9: 367-72.
32. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J. Immunol. 1999; 162: 352-8.
33. Jones TR, Ha J, Williams MA et al. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J. Immunol. 2002; 168: 1123-30.
34. Desai NM, Bassiri H, Kim J et al. Islet allograft, islet xenograft, and skin allograft survival in CD8+ T lymphocyte-deficient mice. Transplantation 1993; 55: 718-22.
35. Haskova Z, Usiu N, Pepose JS, Ferguson TA, Stuart PM. CD4+ T cells are critical for corneal, but not skin, allograft rejection. Transplantation 2000; 69: 483-7.
36. Boisgerault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G. Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation. J. Immunol. 2001; 167: 1891-9.
37. Bishop DK, Shelby J, Eichwald EJ. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4-positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration, and acute allograft rejection. Transplantation 1992; 53: 849-57.
38. Krams SM, Hayashi M, Fox CK et al. CD8+ cells are not necessary for allograft rejection or the induction of apoptosis in an experimental model of small intestinal transplantation. J. Immunol. 1998; 160: 3673-80.
39. Wiseman AC, Pietra BA, Kelly BP, Rayat GR, Rizeq M, Gill RG. Donor IFN-gamma receptors are critical for acute CD4 (+) T cell-mediated cardiac allograft rejection. J. Immunol. 2001; 167: 5457-63.
40. VanBuskirk AM, Wakely ME, Orosz CG. Acute rejection of cardiac allografts by noncytolytic CD4 (+) T cell populations. Transplantation 1996; 62: 300-302.
41. Chan SY, DeBruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155-61.
42. Krieger NR, Yin DP, Fathman CG. CD4+ but not CD8+ cells are essential for allorejection. J. Exp. Med. 1996; 184: 2013-18.
43. Li M, Davey GM, Sutherland RM et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 2001; 166: 6099-103.
44. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 1993; 23: 2242-9.
45. Khammanivong V, Liu XS, Liu WJ et al. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol. Cell Biol. 2003; 81: 1-7.
46. Fishbein TM, Wang L, Benjamin C et al. Successful tolerance induction under CD40 ligation in a rodent small bowel transplant model: first report of a study with the novel antibody AH.F5. Transplantation 2002; 73: 1943-8.
47. Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J. Immunol. 1999; 163: 4805-10.
48. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr. Opin. Immunol. 2002; 14: 592-600.
49. Nathan MJ, Yin D, Eichwald EJ, Bishop DK. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells. Am. J. Transplant. 2002; 2: 323-32.
50. Tung TH, Mackinnon SE, Mohanakumar T. Long-term limb allograft survival using anti-CD40L antibody in a murine model. Transplantation 2003; 75: 644-50.
51. Iwakoshi NN, Markees TG, Turgeon N et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J. Immunol. 2001; 167: 6623-30.
52. Onodera K, Hancock WW, Graser E et al. Th2-type cytokines in the 'infectious' tolerance pathway. Transplant. Proc. 1997; 29: 1290-91.
53. Onodera K, Hancock WW, Graser E et al. Type 2 helper T cell-type cytokines and the development of 'infectious' tolerance in rat cardiac allograft recipients. J. Immunol. 1997; 158: 1572-81.
54. Scully R, Cobbold SP, Mellor AL, Wissing M, Arnold B, Waldmann H. A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection. Eur. J. Immunol. 1997; 27: 1663-70.